ATE73349T1 - Hepatitisoberflaechenantigenpartikelvakzin. - Google Patents

Hepatitisoberflaechenantigenpartikelvakzin.

Info

Publication number
ATE73349T1
ATE73349T1 AT85107328T AT85107328T ATE73349T1 AT E73349 T1 ATE73349 T1 AT E73349T1 AT 85107328 T AT85107328 T AT 85107328T AT 85107328 T AT85107328 T AT 85107328T AT E73349 T1 ATE73349 T1 AT E73349T1
Authority
AT
Austria
Prior art keywords
surface antigen
hepatitis
vaccines
hepatitis surface
antigen particle
Prior art date
Application number
AT85107328T
Other languages
English (en)
Inventor
Pablo D T Valenzuela
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24491503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE73349(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE73349T1 publication Critical patent/ATE73349T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT85107328T 1984-06-18 1985-06-13 Hepatitisoberflaechenantigenpartikelvakzin. ATE73349T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62175684A 1984-06-18 1984-06-18
EP85107328A EP0174444B1 (de) 1984-06-18 1985-06-13 Hepatitisoberflächenantigenpartikelvakzin

Publications (1)

Publication Number Publication Date
ATE73349T1 true ATE73349T1 (de) 1992-03-15

Family

ID=24491503

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85107328T ATE73349T1 (de) 1984-06-18 1985-06-13 Hepatitisoberflaechenantigenpartikelvakzin.

Country Status (5)

Country Link
EP (1) EP0174444B1 (de)
AT (1) ATE73349T1 (de)
CA (1) CA1341021C (de)
DE (1) DE3585578D1 (de)
HK (1) HK140095A (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324513A (en) * 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
EP0401941A3 (de) * 1984-07-11 1991-04-17 Takeda Chemical Industries, Ltd. Hepatitis B-Virus-Oberflächen-Antigen und seine Herstellung
JPS6137738A (ja) * 1984-07-31 1986-02-22 Tetsuo Nakamura Ｂ型肝炎ワクチン
IE59389B1 (en) * 1986-05-23 1994-12-23 Merck & Co Inc Method for producing hepatitis b virus core antigen (HBcAg) in yeast
CA1338800C (en) * 1986-06-17 1996-12-17 Michael Houghton Hepatitis delta and diagnostics and vaccines
JPH089637B2 (ja) * 1986-06-18 1996-01-31 財団法人阪大微生物病研究会 Ｂ型肝炎ウイルス抗原とその製造法
AP56A (en) * 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
EP0310178A1 (de) * 1987-09-30 1989-04-05 Merck & Co. Inc. Reinigung des preS2+S-Antigens
DE68929478T2 (de) * 1988-01-29 2004-04-29 Aventis Pasteur Rekombinante CMV-Neutralisierungsproteine
US5547834A (en) * 1988-01-29 1996-08-20 Chiron Corporation Recombinant CMV neutralizing proteins
AT392417B (de) * 1989-09-20 1991-03-25 Immuno Ag Komplex geeignet zur durchfuehrung eines verfahrens zur reinigung von pre-s-hepatitis-b- virus-oberflaechenantigen
LT3988B (en) 1992-02-17 1996-06-25 Fermentas Biotech Inst Recombinant plasmides pfs19, pfps2-48 and pjlfds1 codingsynthesis of human hepatite b of surfice virus antigenes, methods fof producing thereof
RU2116086C1 (ru) * 1997-08-19 1998-07-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Способ вакцинации против вирусного гепатита b
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR76274B (de) * 1981-08-04 1984-08-04 Univ California
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
EP0105141A3 (de) * 1982-09-09 1985-12-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinante DNS Moleküle, Verfahren zu deren Herstellung, deren Verwendung zur Herstellung von Hepatitis B Oberflächen-Antigen (HBsAg) und pharmazeutische Zusammensetzungen die das HBsAg enthalten
EP0401941A3 (de) * 1984-07-11 1991-04-17 Takeda Chemical Industries, Ltd. Hepatitis B-Virus-Oberflächen-Antigen und seine Herstellung

Also Published As

Publication number Publication date
CA1341021C (en) 2000-06-13
EP0174444A2 (de) 1986-03-19
EP0174444A3 (en) 1987-07-29
DE3585578D1 (de) 1992-04-16
EP0174444B1 (de) 1992-03-11
HK140095A (en) 1995-09-08

Similar Documents

Publication Publication Date Title
EP0278940A3 (de) Hepatitis-B-Virus-Oberflächenantigene und sie enthaltende hybride Antigene
ATE73349T1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
FI893702A0 (fi) Foerfarande foer mikrobiologisk framstaellning av humant serumalbumin och andra heterologa proteiner ur jaest.
DE3584866D1 (de) Hybridpartikel-immunogene.
OA08947A (en) Mammalian interleukin-4.
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
CA2020668A1 (en) Fused or hybrid protein comprising viral antigen and lymphokine
AU1013601A (en) Method of inducing and/or enhancing an immune response to tumor antigens
CA2089753A1 (en) Interleukin-2-leukotoxin gene fusions and uses therefor
AU6941287A (en) Vaccines for human respiratory virus
WO2002074920A3 (en) A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
NZ213303A (en) Plasmodium protein, dna sequence and vaccine
DE68926274D1 (de) Rekombinante HBsAg Hybridpartikel, die morphologische Eigenschaften von HBsAg-Antigen haben und eine immunogene Sequenz enthalten, die neutralisierende Antikörper gegen HIV induziert oder die von diesen Antikörpern erkannt ist, Nukleotide Sequenzen, die diese Partikel codieren und sie enthaltende Impfstoffe
AU7547987A (en) Method of preparation and use for feline leukemia virus antigens
EP0496787A4 (en) Novel infectious bursal disease virus
ES2012815A6 (es) Un metodo para producir peptidos antigenicos relacionados con el antigeno p97 asociado a melanoma, y para preparar vacunas que los contienen.
Lasky et al. Production of an HSV subunit vaccine by genetically engineered mammalian cell lines.
FR2580176B1 (fr) Vaccin antirabique avirulent
EP0293201A3 (de) Methode zur Impfung gegen Hepatitis-B-Virus
AU606574B2 (en) Hepatitis b surface antigen formed by recombinant dna techniques, vaccines diagnostics, cell lines and methods of forming same
SU1515698A1 (ru) Рекомбинантная плазмидная днк, кодирующая синтез hbs ag вируса гепатита b, и штамм вируса осповакцины - продуцент hbs ag вируса гепатита b

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked